by TractManager | Feb 16, 2021 | News
SANTA MONICA, CA and HOUSTON, TX – February 16, 2021 —(PRNEWSWIRE)— symplr, a leading global healthcare governance, risk management, and compliance (“GRC”) software-as-a-service (“SaaS”) company, backed by Clearlake Capital Group, L.P. (together with its affiliates,...
by TractManager | Feb 16, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on Eustachian tube balloon dilation (ETBD) for treatment of adults with chronic Eustachian tube dysfunction (ETD) refractory to medical management (MM).Technology Description: ETBD is a minimally invasive transnasal endoscopic...
by TractManager | Feb 12, 2021 | Emerging Technology Report
Evkeeza (evinacumab-dgnb) is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial...
by TractManager | Feb 9, 2021 | Emerging Technology Report
The eXciteOSA Daytime Therapy Device (formerly known as Snoozeal) is a noninvasive electrical muscle stimulation device that delivers electrical pulses through a mouthpiece that sits around the tongue. The system consists of a mouthpiece, a rechargeable control unit...
by TractManager | Feb 8, 2021 | News
These Food and Drug Administration (FDA) developments recently came in:eXciteOSA DeviceOn February 5, 2021, the FDA granted a de novo marketing classification for the eXciteOSA device(Signifier Medical Technologies), a prescription only device intended to reduce...
Recent Comments